Specific Therapy in Transthyretin Amyloid Cardiomyopathy
Heart Failure Clinics · 2024
DOI: 10.1016/j.hfc.2024.03.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Clinics, 2024. Verfasst von Riccardo Saro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), Univers…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Benzoxazoles, Prealbumin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a relatively prevalent cause of morbidity and mortality. Over the recent years, development of disease-modifying treatments has enabled stabilization of the circulating transthyretin tetramer and suppression of its hepatic production, resulting in a remarkable improvement in survival of patients with ATTR-CM. Second-generation drugs for silencing are currently under investigation in randomized clinical trials. In vivo gene editing of transthyretin has been achieving unanticipated suppression of hepatic production in ATTR-CM. Trials of antibodies inducing the active removal of transthyretin amyloid deposits in the heart are ongoing, and evidence has gathered for exceptional spontaneous regression of ATTR-CM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Via P. Valdoni 7, 34100, Trieste, Italy; European Refe…
- Head of Nuclear Medicine Division, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart,…
- Department of Nuclear Medicine, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste, Via P. Valdoni 7, 34100, Trieste, Italy; National Amyloidosis Centre, Division of Medicine, University…
Zitieren
APA
Saro, R., Allegro, V., Merlo, M., Dore, F., Sinagra, G., & Porcari, A. (2024). Specific Therapy in Transthyretin Amyloid Cardiomyopathy. Heart Failure Clinics. https://doi.org/10.1016/j.hfc.2024.03.005
Vancouver
Saro R, Allegro V, Merlo M, Dore F, Sinagra G, Porcari A. Specific Therapy in Transthyretin Amyloid Cardiomyopathy. Heart Failure Clinics. 2024. doi:10.1016/j.hfc.2024.03.005
BibTeX
@article{Saro2024,
author = {Saro, Riccardo and Allegro, Valentina and Merlo, Marco and Dore, Franca and Sinagra, Gianfranco and Porcari, Aldostefano},
title = {Specific Therapy in Transthyretin Amyloid Cardiomyopathy},
journal = {Heart Failure Clinics},
year = {2024},
doi = {10.1016/j.hfc.2024.03.005}
}
EUVIMED